Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Aug 16, 2018 12:16pm

123 Views

Post# 28472525

RE:RE:RE:RE:No news

There's really no point trying to reason with the dreamers.

Mikchicken wrote: All I'm saying is that we can all throw around random numbers like Scoop did. To give a number that is nearly 500% of the current share price is a little aggressive. I have 80,000 shares so I hope like you all do that this thing turns into something but making wild claims about a buyout with the price and the company aren't really constructive.

So go ahead and bash me if you like, I'm just pointing out that making claims like that are based on nothing.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale